Biomarker Technologies and Assay Read-Outs
At Concept Life Sciences we use cutting-edge technology to offer a wide-range of read-outs for accurate analysis in areas such as biomarker discovery, mechanism of action analysis and treatment response assessment. With use of standard analysis platforms and tailored assay read-outs, we can measure the expression of analytes including proteins, genes and other molecular entities. Our in-house experts can advise on the best approach and read-out to use to get the most valuable data for your program of work.
Connected servicesMore informationSpeak to an expertVisualise and quantify cellular responses to your drug treatment through detection of multiple biomarkers on the same tissue section using cutting edge multiplex assays and automated platforms.
Omics based approaches provide a robust and ultrasensitive method for biomarker discovery and justification of targets for therapy. Unbiased methods such as bulk or single-cell RNA-seq (scRNA-Seq, using the 10x Genomics® Chromium™ System) can be used to identify targets and investigate molecular signatures of disease.
Cell profiling can be approached using multiple technologies such as high-content imaging to assess cell morphology and characteristics, and flow cytometry to investigate extracellular, intracellular and intranuclear markers and other parameters such as cell signalling pathways.
From early stage-predictive toxicology, mechanism of action or assessment of therapeutic effect, our robust multiplex immunoassays offers the ability to assess up to 65 analytes from the same sample using a low sample volume.
Biophysical techniques such as Grating-Coupled Interferometry (GCI) and Surface Plasmon Resonance (SPR) allow direct, label-free and quantitative detection of biomarkers. They offer multiple advantages such as non-destructive analysis, rapid and real-time monitoring of the target biomolecules, excellent selectivity, reliability, and cost-efficacy.
Bioanalytical techniques such as liquid chromatography-mass spectrometry (LC-MS) allow for quantitative analysis of biomarkers from multiple sources (such as patient-derived samples including serum, plasma, urine and tissues, as well as cells and culture medium) with high levels of sensitivity and specificity.
These techniques allow for accurate identification of reliable biomarkers, mechanism of action insight and measurement of therapeutic responses.